Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination.

Campo JJ, Le TQ, Pablo JV, Hung C, Teng AA, Tettelin H, Tate A, Hanage WP, Alderson MR, Liang X, Malley R, Lipsitch M, Croucher NJ.

Elife. 2018 Dec 28;7. pii: e37015. doi: 10.7554/eLife.37015.

2.

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.

Chen WH, Neuzil KM, Boyce CR, Pasetti MF, Reymann MK, Martellet L, Hosken N, LaForce FM, Dhere RM, Pisal SS, Chaudhari A, Kulkarni PS, Borrow R, Findlow H, Brown V, McDonough ML, Dally L, Alderson MR.

Lancet Infect Dis. 2018 Oct;18(10):1088-1096. doi: 10.1016/S1473-3099(18)30400-6. Epub 2018 Aug 14.

PMID:
30120069
3.

Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics.

Vekemans J, Moorthy V, Friede M, Alderson MR, Sobanjo-Ter Meulen A, Baker CJ, Heath PT, Madhi SA, Mehring-Le Doare K, Saha SK, Schrag S, Kaslow DC.

Vaccine. 2018 Feb 2. pii: S0264-410X(17)31359-2. doi: 10.1016/j.vaccine.2017.09.087. [Epub ahead of print] Review.

4.

Panel 6: Vaccines.

Pettigrew MM, Alderson MR, Bakaletz LO, Barenkamp SJ, Hakansson AP, Mason KM, Nokso-Koivisto J, Patel J, Pelton SI, Murphy TF.

Otolaryngol Head Neck Surg. 2017 Apr;156(4_suppl):S76-S87. doi: 10.1177/0194599816632178. Review.

5.

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.

Kobayashi M, Schrag SJ, Alderson MR, Madhi SA, Baker CJ, Sobanjo-Ter Meulen A, Kaslow DC, Smith PG, Moorthy VS, Vekemans J.

Vaccine. 2016 Dec 22. pii: S0264-410X(16)31236-1. doi: 10.1016/j.vaccine.2016.12.029. [Epub ahead of print]

6.

Status of research and development of pediatric vaccines for Streptococcus pneumoniae.

Alderson MR.

Vaccine. 2016 Jun 3;34(26):2959-2961. doi: 10.1016/j.vaccine.2016.03.107. Epub 2016 Apr 12.

7.

Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine.

Hu L, Joshi SB, Liyanage MR, Pansalawatta M, Alderson MR, Tate A, Robertson G, Maisonneuve J, Volkin DB, Middaugh CR.

J Pharm Sci. 2013 Feb;102(2):387-400. doi: 10.1002/jps.23375. Epub 2012 Nov 18.

PMID:
23161162
8.

Issues and challenges in the development of pneumococcal protein vaccines.

Ginsburg AS, Nahm MH, Khambaty FM, Alderson MR.

Expert Rev Vaccines. 2012 Mar;11(3):279-85. doi: 10.1586/erv.12.5. Review.

9.

New conjugate vaccines for the prevention of pneumococcal disease in developing countries.

Ginsburg AS, Alderson MR.

Drugs Today (Barc). 2011 Mar;47(3):207-14. doi: 10.1358/dot.2011.47.3.1556471. Review.

PMID:
21494698
10.

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ, Orme IM, Skeiky YA, Alderson MR, Cowgill KD, Prieels JP, Abalos RM, Dubois MC, Cohen J, Mettens P, Lobet Y.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2301-6. doi: 10.1073/pnas.0712077106. Epub 2009 Feb 2. Erratum in: Proc Natl Acad Sci U S A.2009 May 5;106(18):7678. Dalemans, Wilifred [corrected to Dalemans, Wilfried].

11.

Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning.

Coler RN, Dillon DC, Skeiky YA, Kahn M, Orme IM, Lobet Y, Reed SG, Alderson MR.

Vaccine. 2009 Jan 7;27(2):223-33. doi: 10.1016/j.vaccine.2008.10.056. Epub 2008 Nov 8.

12.

TLR4 agonists as immunomodulatory agents.

Alderson MR, McGowan P, Baldridge JR, Probst P.

J Endotoxin Res. 2006;12(5):313-9.

PMID:
17059695
13.

Immunogenicity of Mycobacterium tuberculosis antigens in Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle.

Mustafa AS, Skeiky YA, Al-Attiyah R, Alderson MR, Hewinson RG, Vordermeier HM.

Infect Immun. 2006 Aug;74(8):4566-72.

14.

Secreted proteins from Mycobacterium tuberculosis gain access to the cytosolic MHC class-I antigen-processing pathway.

Lewinsohn DM, Grotzke JE, Heinzel AS, Zhu L, Ovendale PJ, Johnson M, Alderson MR.

J Immunol. 2006 Jul 1;177(1):437-42.

15.

Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis.

Tsenova L, Harbacheuski R, Moreira AL, Ellison E, Dalemans W, Alderson MR, Mathema B, Reed SG, Skeiky YA, Kaplan G.

Infect Immun. 2006 Apr;74(4):2392-401.

16.

Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein.

Irwin SM, Izzo AA, Dow SW, Skeiky YA, Reed SG, Alderson MR, Orme IM.

Infect Immun. 2005 Sep;73(9):5809-16.

17.

Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41.

Skeiky YA, Alderson MR, Ovendale PJ, Lobet Y, Dalemans W, Orme IM, Reed SG, Campos-Neto A.

Vaccine. 2005 Jun 10;23(30):3937-45. Epub 2005 Mar 30.

PMID:
15917115
18.

Differential regulation of inflammatory cytokine secretion by human dendritic cells upon Chlamydia trachomatis infection.

Gervassi A, Alderson MR, Suchland R, Maisonneuve JF, Grabstein KH, Probst P.

Infect Immun. 2004 Dec;72(12):7231-9.

19.

Human CD8+ T cells recognize the 60-kDa cysteine-rich outer membrane protein from Chlamydia trachomatis.

Gervassi AL, Grabstein KH, Probst P, Hess B, Alderson MR, Fling SP.

J Immunol. 2004 Dec 1;173(11):6905-13.

20.

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, Basaraba RJ, Izzo AA, Lasco TM, Chapman PL, Reed SG, Orme IM.

Infect Immun. 2004 Nov;72(11):6622-32.

21.

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein.

Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, Campos-Neto A, Lobet Y, Dalemans W, Orme IM, Reed SG.

J Immunol. 2004 Jun 15;172(12):7618-28.

22.

Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design.

Vekemans J, Ota MO, Sillah J, Fielding K, Alderson MR, Skeiky YA, Dalemans W, McAdam KP, Lienhardt C, Marchant A.

Infect Immun. 2004 Jan;72(1):381-8.

23.

An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response.

Starnbach MN, Loomis WP, Ovendale P, Regan D, Hess B, Alderson MR, Fling SP.

J Immunol. 2003 Nov 1;171(9):4742-9.

24.

Functional characterization of class Ia- and non-class Ia-restricted Chlamydia-reactive CD8+ T cell responses in humans.

Gervassi AL, Probst P, Stamm WE, Marrazzo J, Grabstein KH, Alderson MR.

J Immunol. 2003 Oct 15;171(8):4278-86.

25.

Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells.

Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM.

Am J Respir Crit Care Med. 2003 Dec 1;168(11):1346-52. Epub 2003 Sep 11.

PMID:
12969871
26.

Prospects for a better vaccine against tuberculosis.

Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YA.

Tuberculosis (Edinb). 2003;83(1-3):213-9. Review.

PMID:
12758214
27.

Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis.

Coler RN, Campos-Neto A, Ovendale P, Day FH, Fling SP, Zhu L, Serbina N, Flynn JL, Reed SG, Alderson MR.

J Immunol. 2001 May 15;166(10):6227-35.

28.

Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity.

Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, Grabstein KH, Alderson MR.

J Immunol. 2001 Jan 1;166(1):439-46.

29.

T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection.

Skeiky YA, Ovendale PJ, Jen S, Alderson MR, Dillon DC, Smith S, Wilson CB, Orme IM, Reed SG, Campos-Neto A.

J Immunol. 2000 Dec 15;165(12):7140-9.

30.

Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG.

Dillon DC, Alderson MR, Day CH, Bement T, Campos-Neto A, Skeiky YA, Vedvick T, Badaro R, Reed SG, Houghton R.

J Clin Microbiol. 2000 Sep;38(9):3285-90.

31.

Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction.

Lewinsohn DM, Briden AL, Reed SG, Grabstein KH, Alderson MR.

J Immunol. 2000 Jul 15;165(2):925-30.

32.

Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells.

Alderson MR, Bement T, Day CH, Zhu L, Molesh D, Skeiky YA, Coler R, Lewinsohn DM, Reed SG, Dillon DC.

J Exp Med. 2000 Feb 7;191(3):551-60.

33.

Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis.

Skeiky YA, Lodes MJ, Guderian JA, Mohamath R, Bement T, Alderson MR, Reed SG.

Infect Immun. 1999 Aug;67(8):3998-4007.

34.

Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family.

Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T, Campos-Neto A, Skeiky YA, Orme IM, Roberts A, Steen S, Dalemans W, Badaro R, Reed SG.

Infect Immun. 1999 Jun;67(6):2941-50.

35.

Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis.

Coler RN, Skeiky YA, Vedvick T, Bement T, Ovendale P, Campos-Neto A, Alderson MR, Reed SG.

J Immunol. 1998 Sep 1;161(5):2356-64.

36.

Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis.

Webb JR, Vedvick TS, Alderson MR, Guderian JA, Jen SS, Ovendale PJ, Johnson SM, Reed SG, Skeiky YA.

Infect Immun. 1998 Sep;66(9):4208-14.

37.

Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells.

Lewinsohn DM, Alderson MR, Briden AL, Riddell SR, Reed SG, Grabstein KH.

J Exp Med. 1998 May 18;187(10):1633-40.

38.

Receptors and ligands that mediate activation-induced death of T cells.

Alderson MR, Lynch DH.

Springer Semin Immunopathol. 1998;19(3):289-300. Review. No abstract available.

PMID:
9540157
39.

Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms.

Lewinsohn DM, Bement TT, Xu J, Lynch DH, Grabstein KH, Reed SG, Alderson MR.

J Immunol. 1998 Mar 1;160(5):2374-9.

40.

CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis.

Campos-Neto A, Ovendale P, Bement T, Koppi TA, Fanslow WC, Rossi MA, Alderson MR.

J Immunol. 1998 Mar 1;160(5):2037-41.

41.

CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells.

Koppi TA, Tough-Bement T, Lewinsohn DM, Lynch DH, Alderson MR.

Eur J Immunol. 1997 Dec;27(12):3161-5.

PMID:
9464801
42.

The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation.

Spriggs MK, Armitage RJ, Comeau MR, Strockbine L, Farrah T, Macduff B, Ulrich D, Alderson MR, Müllberg J, Cohen JI.

J Virol. 1996 Aug;70(8):5557-63.

43.

Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation.

Yao Z, Maraskovsky E, Spriggs MK, Cohen JI, Armitage RJ, Alderson MR.

J Immunol. 1996 May 1;156(9):3260-6.

PMID:
8617948
44.

CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages.

Kennedy MK, Picha KS, Fanslow WC, Grabstein KH, Alderson MR, Clifford KN, Chin WA, Mohler KM.

Eur J Immunol. 1996 Feb;26(2):370-8.

PMID:
8617306
45.
46.

Immunoregulatory effects of Fas-mediated signalling.

Lynch DH, Alderson MR, Ramsdell F.

J Cell Biochem. 1996 Jan;60(1):39-46. Review. No abstract available.

PMID:
8825414
47.

Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes.

Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV.

J Virol. 1996 Jan;70(1):199-206.

48.

Fas and FasL in the homeostatic regulation of immune responses.

Lynch DH, Ramsdell F, Alderson MR.

Immunol Today. 1995 Dec;16(12):569-74. Review.

PMID:
8579749
49.

A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.

Müllberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D, Black RA, Mohler KM.

J Immunol. 1995 Dec 1;155(11):5198-205.

PMID:
7594530
50.

B-cell stimulation.

Armitage RJ, Alderson MR.

Curr Opin Immunol. 1995 Apr;7(2):243-7. Review.

PMID:
7546384

Supplemental Content

Loading ...
Support Center